Subacute toxicity and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, J | - |
dc.contributor.author | Shin, HC | - |
dc.contributor.author | Kim, JC | - |
dc.contributor.author | Kim, B | - |
dc.date.accessioned | 2022-02-18T07:42:15Z | - |
dc.date.available | 2022-02-18T07:42:15Z | - |
dc.date.created | 2022-02-18 | - |
dc.date.issued | 2004-03 | - |
dc.identifier.issn | 0278-6915 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hongik/handle/2020.sw.hongik/25792 | - |
dc.description.abstract | The subacute toxicity and toxicokinetics of a type IV phosphodiesterase inhibitor, CJ-10882, were evaluated after single (on the 1st day) and 4-week (on the 27th day) oral administration of the drug, in doses of 0 (to serve as a control), 2, 10 and 50 mg/kg/day, to male and female dogs (n = 3 for male and female dogs for each dose). During the test period, clinical signs, mortality, body weight, food consumption, ophthalmoscopy, urinalysis, hematology, serum biochemistry, gross findings, organ weight and histopathology were examined. The 4-week repeated oral doses of CJ-10882 resulted in salivation, vomiting, and atrophy of the thymus. The absolute toxic dose was 50 mg/kg/day and the level at which no adverse effects were observed was 2 mg/kg/day for male and female dogs. There were no significant gender differences in the pharmacokinctic parameters of CJ-10882 for each dose after both single and 4-week oral administration. The pharmacokinetic parameters of CJ-10882 were dose independent after a single oral administration; the time to reach a peak plasma concentration (T-max) and the dose-normalized area under the plasma concentration-time curve from time zero to 8 h in plasma (AUC(0-8 h)) were not significantly different among three doses. The accumulation of CJ-10882 after 4-week oral administration was not notable at the toxic dose of 50 mg/kg/day. For example, after 4-week administration, the dose-normalized AUC(0-8 h) Value at 50 mg/kg/day (0.132 mug h/ml) was not significantly greater than that at 10 mg/kg/day (0.131 mug h/ml). After 4-week oral administration, the dose-normalized C-max and AUC(0-8 h) at 50 mg/kg/day were not significantly higher and greater, respectively, than those after the single oral administration. (C) 2004 Elsevier Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | CYCLIC-AMP | - |
dc.subject | ANTIINFLAMMATORY DRUGS | - |
dc.subject | PDE4 INHIBITORS | - |
dc.subject | THEOPHYLLINE | - |
dc.subject | BIOSYNTHESIS | - |
dc.subject | ROLIPRAM | - |
dc.subject | BINDING | - |
dc.subject | AGENTS | - |
dc.subject | FERRET | - |
dc.title | Subacute toxicity and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, B | - |
dc.identifier.doi | 10.1016/j.fct.2003.09.011 | - |
dc.identifier.scopusid | 2-s2.0-1042302140 | - |
dc.identifier.wosid | 000220164800005 | - |
dc.identifier.bibliographicCitation | FOOD AND CHEMICAL TOXICOLOGY, v.42, no.3, pp.373 - 380 | - |
dc.relation.isPartOf | FOOD AND CHEMICAL TOXICOLOGY | - |
dc.citation.title | FOOD AND CHEMICAL TOXICOLOGY | - |
dc.citation.volume | 42 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 373 | - |
dc.citation.endPage | 380 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Food Science & Technology | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.relation.journalWebOfScienceCategory | Food Science & Technology | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.subject.keywordPlus | CYCLIC-AMP | - |
dc.subject.keywordPlus | ANTIINFLAMMATORY DRUGS | - |
dc.subject.keywordPlus | PDE4 INHIBITORS | - |
dc.subject.keywordPlus | THEOPHYLLINE | - |
dc.subject.keywordPlus | BIOSYNTHESIS | - |
dc.subject.keywordPlus | ROLIPRAM | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordPlus | FERRET | - |
dc.subject.keywordAuthor | CJ-10882 | - |
dc.subject.keywordAuthor | subacute toxicity | - |
dc.subject.keywordAuthor | toxicokinetics | - |
dc.subject.keywordAuthor | 4-week oral administration | - |
dc.subject.keywordAuthor | dogs | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
94, Wausan-ro, Mapo-gu, Seoul, 04066, Korea02-320-1314
COPYRIGHT 2020 HONGIK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.